Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
Table 1
Baseline characteristics.
Overall (n = 45)
FEP (n = 22)
MEM (n = 10)
TZP (n = 13)
value
Age, mean (SD)
55.3 (35.9–74.8)
54.9 (37.9–72.0)
58.2 (36.8–79.6)
53.8 (30.8–76.7)
0.86
Gender, male
26 (58)
13 (59)
6 (60)
7 (53.8)
0.94
Race
0.48
White
26 (58)
15 (68.2)
4 (40.0)
7 (53.8)
Black or African American
9 (20)
5 (22.7)
2 (20)
2 (15.4)
Others
10 (22)
2 (9.1)
4 (40)
4 (30.8)
SOFA score, mean (SD)
7.5 (3.9–11.1)
7.9 (4.5–11.4)
7.4 (3.6–11.3)
6.8 (3.0–10.6)
0.73
Charlson comorbidity score, median (IQR)
4.0 (0–8)
3.1 (1.1–5.3)
3.8 (1.1–6.5)
3.5 (0.6–6.5)
0.74
Polymicrobial infection
30 (67)
14 (63.6)
8 (80)
8 (61.5)
0.59
Coinfection
21 (47)
13 (59.1)
3 (30)
6 (46.2)
0.30
ICU admission
39 (87)
21 (95.5)
7 (70.0)
11 (84.6)
0.14
Vasopressors during ICU stay
29 (74)
18 (81.8)
5 (50.0)
6 (46.2)
0.13
Vasopressors at the start of antibiotics
18 (40)
10 (45.5)
4 (40.0)
4 (66.7)
0.33
Mechanical ventilation
35 (90)
18 (81.8)
7 (70.0)
10 (76.9)
0.71
MSSA pneumonia
33 (73)
6 (27.3)
2 (20.0)
4 (30.8)
0.84
No initial source control
12 (27)
6 (50)
3 (25)
3 (25)
0.93
Time to source control, mean (SD)
5.7 (1.4–10)
5.4 (−0.28–11.1)
7 (5–9)
4.5 (−0.5–9.5)
0.84
n (%) unless otherwise stated. SD: standard deviation; ICU: intensive care unit, IQR: interquartile range; SOFA: Sequential organ failure assessment; MSSA: methicillin-sensitive Staphylococcus aureus; FEP: cefepime; MEM: meropenem; TZP: piperacillin-tazobactam.
